about the author

Amber Tong

amber@endpointsnews.com @AmberTongPW
Amber Tong on LinkedIn

author articles

How durable is durable? Bio­Marin gears up to bring he­mo­phil­ia A gene ther­a­py to FDA again with 2-year da­ta

4 years ago
R&D
Cell/Gene Tx

Three AI deals kick off #JPM22 week­end; Can Sil­i­con Val­ley change how sci­ence gets fund­ed?; Spe­cial re­port: 2021 new ...

4 years ago
Weekly

Plant­i­ng an­oth­er flag on Pfiz­er and Al­ny­lam's turf, As­traZeneca grabs amy­loi­do­sis drug from the biotech that in­vent­ed ...

4 years ago
Deals

Gary Glick puts Odyssey's $218M cash stack to use, ac­quir­ing ma­chine learn­ing out­fit

4 years ago
Deals
AI

You know AAV and LNP. What about PLV? Eli Lil­ly lines up new ve­hi­cle to de­liv­er its ge­net­ic med­i­cines

4 years ago
Deals
Cell/Gene Tx

Can RNA edit­ing take At­las start­up where Ver­tex could­n't go? Ko­r­ro lands $116M to find out

4 years ago
Financing
Cell/Gene Tx

As­traZeneca hands off epilep­sy pro­grams to Ovid; Amy­lyx scores pri­or­i­ty re­view for ALS drug 

4 years ago
News Briefing

Biotech pulls plans to file ac­cel­er­at­ed ap­proval af­ter FDA 'change in di­rec­tion' — shares plum­met

4 years ago
FDA+

Low-pro­file RNAi play­er lands on HKEX fol­low­ing mod­est $50M IPO

4 years ago
Financing
China

It's a year late, but No­var­tis has fi­nal­ly steered in­clisir­an to FDA ap­proval. Will it sell?

4 years ago
Pharma
FDA+

'He re­peat­ed­ly lied': Feds pile on as Har­vard chemist Charles Lieber con­vict­ed of ly­ing about Chi­nese ties

4 years ago
People
China

No­var­tis un­wraps $1.5B gene ther­a­py buy­out — beef­ing up ar­se­nal against reti­nal dis­eases

4 years ago
Deals
Cell/Gene Tx

One of Pfiz­er’s Duchenne gene ther­a­py tri­als put on hold in wake of pa­tient death as high-dose AAV con­cerns still ...

4 years ago
R&D
Cell/Gene Tx

Pounc­ing on next-gen I/O play, Sanofi ac­quires Amu­nix for $1B+ and picks up 'u­ni­ver­sal mask' tech

4 years ago
Deals

Ab­b­Vie pe­ti­tions trade com­mis­sion to ban Alvotech's Hu­mi­ra biosim­i­lar; Cy­to­ki­net­ics li­cens­es heart drug to Chi­nese ...

4 years ago
News Briefing

Tim Lu takes Sen­ti and its gene cir­cuit tech pub­lic in $296M deal rid­ing on Omid Farokhzad's SPAC

4 years ago
Deals

No­var­tis turns to BeiGene again for the next big check­point tar­get, pay­ing $300M to jump in­to TIG­IT race

4 years ago
Deals
China

Truce: Mod­er­na backs down in patent fight with NIH as it touts ear­ly boost­er da­ta against Omi­cron

4 years ago
R&D
Coronavirus

It’s be­gin­ning to look a lot like M&A sea­son; Aduhelm runs in­to more re­sis­tance; Eli Lil­ly, Bris­tol My­ers get in ...

4 years ago
Weekly

Ipsen fronts $136M to bag Gen­fit's once-failed NASH drug, bet­ting on its po­ten­tial in rare liv­er con­di­tion

4 years ago
Deals

Ital­ian can­cer gene ther­a­py biotech makes his­to­ry with mod­est Nas­daq IPO

4 years ago
Financing

Sanofi and Glax­o­SmithK­line: Those PhI­II Covid-19 vac­cine re­sults you’ve been wait­ing for? Wait longer (but here's ...

4 years ago
Pharma
Coronavirus

No­var­tis en­lists Mol­e­c­u­lar Part­ners on ra­di­oli­gand ther­a­py dis­cov­ery; Galera blames CRO er­ror for PhI­II fail­ure — ...

4 years ago
News Briefing

M&A sea­son starts ear­ly? CSL seals $11.7B ac­qui­si­tion of Vi­for Phar­ma

4 years ago
Deals
First page Previous page 39404142434445 Next page Last page
A service from the Financial Times